Mark A. Velleca, Director at G1 Therapeutics, Inc. (GTHX), sold 40,000 shares at $20.88 ($845K) on 2021-01-19, disclosed to the SEC on 2021-01-21.
Seasonal sale ($845k) by Director — this insider has traded GTHX in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.88 | 10,000 | $209K | 24.7% |
| 2 | $21.51 | 10,000 | $215K | 25.4% |
| 3 | $21.51 | 10,000 | $215K | 25.4% |
| 4 | $20.64 | 10,000 | $206K | 24.4% |
| Total | $21.14 avg | 40,000 | $845K | 100% |
| Filing → |
| GTHX | SELL | 2022-09-22 | $270K | — | Filing → |
| GTHX | SELL | 2022-08-18 | $1.0M | — | Filing → |
| GTHX | SELL | 2021-07-15 | $946K | — | Filing → |